Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Court sided with Korean drugmakers for Hepsera case
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 9, 2012 02:46:43
The Korean Intellectual Property Tribunal sided with generic drug makers, ruling that the composition patient on Hepsera is invalid, sources said Friday.

The Tribunal’s ruling is final as Gilead didn’t appeal to the high court after the Patent Court sided with generic drug makers on July 20.

Hepsera is marketed as hepatitis B treatment although it was developed to treat HIV infection. Since renal toxicity was found with 60mg, 10mg, a much lower strength, is used to treat hepatitis B.

Ahn So Young, attorney for Korean drugmakers, said, “The court stopped multinational companies’ patent evergreening again.”

The latest ruling doesn’t seem to affect the current market much. Generic versions of Hepsera hold only about 30% market share. Jeil, Samjin, Dasan Medichem, Chong Kung Dang, United Korea, Bukwang, and Dongwha participated Hepsera’s case.

Baraclude is No.1 drug in the hepatitis B drug market. Hepsera is losing its ground to Baraclude.

 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com